Proteomics in Small Cell Lung Cancer

Abroad (travel likely)Recruiting

Conditions

Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Aalborg University Hospital, Aalborg, Region North Jutland, Denmark
Contact: Study coordinator (Weronika Maria Szejniuk, MD, PhD) · wms@rn.dk · 97661524

Study leads

Weronika Szejniuk, MD, PhD
Principal Investigator
Aalborg University Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE3

Phoenix, United States · Burbank, United States

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Non-Small Cell Lung Cancer · Small Cell Lung Cancer · Extrapulmonary Small Cell Cancer

Abroad (travel likely)Recruiting

Bethesda, United States

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Orange, United States · Skokie, United States

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Tucson, United States